tbc1d23 Antibody

What epitopes should researchers target when selecting TBC1D23 antibodies?

TBC1D23 contains several functional domains that can be targeted for antibody generation. Based on recent research, antibodies targeting the N-terminal region (residues 1-21) are particularly useful for studying interactions with golgin-97 and golgin-245, as this region is critical for direct binding . For experiments exploring the TBC1D23-FAM91A1 complex, antibodies targeting residues 514-543 of TBC1D23 would be more appropriate, as this region forms an important binding interface . When selecting antibodies, researchers should consider which domain of TBC1D23 is most relevant to their specific research question.

How can researchers validate the specificity of TBC1D23 antibodies?

Validation of TBC1D23 antibodies should include multiple approaches:

• Western blotting comparing wild-type cells with CRISPR-generated Δtbc1d23 knockout cells as described in the literature

• Immunoprecipitation followed by mass spectrometry to confirm binding partners match known TBC1D23 interactors such as golgin-97, golgin-245, and FAM91A1

• Immunofluorescence comparing antibody staining patterns in wild-type versus knockout cells, with known Golgi/endosomal markers as references

• Recombinant protein expression and antibody binding tests using GST-TBC1D23 fusion proteins as described in affinity chromatography protocols

What are the recommended fixation methods for TBC1D23 immunofluorescence studies?

For optimal immunofluorescence detection of TBC1D23, researchers should consider fixation protocols that preserve membrane structures. Based on published methodologies, both paraformaldehyde fixation (4%, 15 minutes at room temperature) and methanol fixation (-20°C, 5 minutes) have been used successfully. Paraformaldehyde fixation better preserves spatial relationships between TBC1D23 and its binding partners at the Golgi apparatus, while methanol fixation may expose certain epitopes more effectively, particularly when studying TBC1D23's interactions with the WASH complex and FAM21A . Optimization with both methods is recommended for new antibodies.

How should researchers design experiments to distinguish between TBC1D23's roles in vesicle tethering versus other functions?

Distinguishing TBC1D23's direct role in vesicle tethering from its other potential functions requires carefully designed experiments:

• Generate mitochondrial-targeted TBC1D23 fusion proteins (TBC1D23-mito) following published protocols to assess direct vesicle capture capabilities

• Compare results with mitochondrial-targeted golgin-97/245 to distinguish TBC1D23-dependent effects

• Perform electron microscopy to visualize tethered vesicles at high resolution, measuring the distance between tethered carriers and mitochondrial membranes

• Include controls with truncated variants lacking specific functional domains (particularly the FAM21A binding region at residues 559-684)

• Employ live-cell imaging techniques with fluorescently tagged TBC1D23 and cargo proteins to capture dynamic tethering events

This approach allows researchers to separate TBC1D23's direct vesicle tethering functions from potential signaling or regulatory roles in endosome-to-Golgi trafficking.

What are the optimal antibody combinations for studying TBC1D23 complexes with FAM91A1?

To effectively study TBC1D23-FAM91A1 complexes, researchers should employ the following antibody combination strategy:

When performing co-immunoprecipitation experiments, researchers should include appropriate controls with ΔFAM91A1 cells to confirm specificity, as studies have shown that while FAM91A1 is recruited by TBC1D23, it is not essential for vesicle capture by TBC1D23 or mitochondrial golgin-97 .

How can researchers experimentally distinguish functional impacts of TBC1D23 mutations associated with pontocerebellar hypoplasia?

To evaluate the functional consequences of TBC1D23 mutations identified in pontocerebellar hypoplasia:

• Generate cell lines expressing wild-type and mutant forms of TBC1D23 in Δtbc1d23 backgrounds using CRISPR-Cas9 technology as described in the literature

• Assess protein-protein interactions of mutant proteins with known binding partners (golgin-97/245, FAM91A1) using co-immunoprecipitation and proximity labeling approaches

• Compare endosome-to-Golgi trafficking efficiency of model cargoes (TGN46, CI-MPR) between wild-type and mutant cells using established antibody uptake assays

• Measure levels of steady-state TGN46 as a quantitative readout of trafficking defects

• Test the ability of mutant TBC1D23 to capture vesicles in the mitochondrial relocation assay compared to wild-type protein

The interaction between FAM91A1 and TBC1D23 can specifically be used to predict the risk of certain TBC1D23-associated mutations to pontocerebellar hypoplasia .

What protocol modifications are needed when using TBC1D23 antibodies for immunoprecipitation of endogenous versus overexpressed protein?

When conducting immunoprecipitation experiments with TBC1D23 antibodies, researchers should consider these protocol modifications:

For endogenous TBC1D23:

• Use higher antibody concentrations (5-10 μg per mg of lysate)

• Extend incubation time to overnight at 4°C

• Use gentle lysis buffers containing 0.5% Triton X-100 to preserve interactions

• Include phosphatase inhibitors to maintain post-translational modifications

For overexpressed GFP-tagged TBC1D23:

• Utilize GFP-Trap beads for more efficient capture as described in the literature

• Reduce incubation time to 2 hours with rotation at 4°C

• Consider crosslinking approaches for transient interactions

• Wash with higher stringency buffers to reduce non-specific binding

Both approaches should include appropriate controls using Δtbc1d23 cells or unrelated antibodies to confirm specificity of detected interactions.

What are the optimal experimental conditions for detecting TBC1D23-mediated vesicle tethering in live cells?

For live cell visualization of TBC1D23-mediated vesicle tethering:

• Culture cells in glass-bottomed dishes suitable for high-resolution imaging

• Co-transfect with plasmids encoding fluorescently tagged TBC1D23 (mCherry) and interaction partners like FAM91A1 (GFP) as described in the high-resolution time-lapse imaging protocols

• Begin imaging 24 hours post-transfection using confocal microscopy with a 100× oil immersion objective

• Capture images every 30 seconds for at least 30 minutes to document dynamic trafficking events

• Maintain cells at 37°C with 5% CO₂ throughout imaging

• Include appropriate controls with mutated TBC1D23 lacking key binding domains

This approach allows researchers to visualize the dynamic process of vesicle capture and tethering mediated by TBC1D23 in real-time.

How should researchers interpret conflicting TBC1D23 antibody results in different cell types?

When faced with conflicting TBC1D23 antibody results across different cell types, researchers should systematically investigate:

• Cell-type specific expression levels of TBC1D23 binding partners (golgin-97/245, FAM91A1) that may affect localization patterns

• Differences in endosome-to-Golgi trafficking demands between cell types that might influence TBC1D23 distribution

• Alternative splicing of TBC1D23 that might generate cell-type specific isoforms with different epitope accessibility

• Post-translational modifications that could be cell-type specific and mask antibody epitopes

For systematic analysis, perform parallel experiments in multiple cell lines (HeLa, HEK293T, and tissue-specific lines) using standardized protocols, and validate antibody specificity in each system using siRNA knockdown or CRISPR knockout approaches .

How can researchers effectively study the role of TBC1D23 in pontocerebellar hypoplasia using antibody-based approaches?

To investigate TBC1D23's role in pontocerebellar hypoplasia:

• Develop cellular models expressing disease-associated biallelic mutations in TBC1D23 using CRISPR-Cas9 genome editing

• Use validated TBC1D23 antibodies to compare protein localization and levels between wild-type and mutant cells

• Employ proximity labeling techniques to identify differences in TBC1D23 interaction networks in disease models

• Analyze endosome-to-Golgi trafficking efficiency of key cargoes (TGN46, CI-MPR) in patient-derived cells versus controls

• Investigate potential immune system effects by measuring inflammatory markers and cytokine levels before and after bacterial challenges

This systematic approach allows researchers to determine how disease-causing mutations affect TBC1D23 function at molecular, cellular, and systemic levels.

What experimental design is optimal for studying TBC1D23's role in cancer progression using antibodies?

For studying TBC1D23's role in cancer progression:

• Compare TBC1D23 expression levels in matched normal versus tumor tissues using immunohistochemistry with validated antibodies

• Correlate expression with clinicopathological features (tumor size, differentiation, metastasis, TNM stage) as demonstrated in NSCLC studies

• Develop stable knockdown and overexpression cell lines using approaches described in the literature

• Analyze cell proliferation, migration, and invasion phenotypes using standard assays (MTT, colony formation, scratch assay, transwell)

• Investigate molecular mechanisms by examining TBC1D23's interaction with cancer-relevant partners like RAB11A and β1-integrin using co-immunoprecipitation and immunofluorescence

This comprehensive approach connects TBC1D23 expression levels to functional cancer-related phenotypes and mechanistic pathways.

How can researchers optimize TBC1D23 antibodies for proximity labeling experiments?

To optimize TBC1D23 antibodies for proximity labeling:

• Generate BioID or TurboID fusion constructs with TBC1D23, placing the biotin ligase at either N- or C-terminus based on known interaction domains

• Validate fusion protein functionality by confirming its ability to rescue trafficking defects in Δtbc1d23 cells

• Perform proximity labeling experiments using standardized protocols with appropriate controls:

  • Compare results between N- and C-terminal fusions to identify position-specific interactors

  • Include mitochondrial-targeted TBC1D23-BirA* constructs to identify vesicle-associated proteins

  • Use SILAC labeling to quantitatively compare wild-type versus mutant TBC1D23 interactomes

This approach has successfully identified TBC1D23 interactors including golgin-97, golgin-245, FAM91A1, and endosome-derived carrier cargo proteins .

What are the most effective strategies for detecting cargo-selective vesicle tethering mediated by TBC1D23?

Recent research reveals that TBC1D23 mediates cargo-selective vesicle tethering through recognition of motifs shared by cargo proteins . To effectively study this:

• Develop fluorescently tagged constructs of both TBC1D23 and candidate cargo proteins

• Establish the mitochondrial relocation assay using TBC1D23-mito fusion proteins to directly visualize cargo capture

• Compare tethering efficiency between different cargo proteins to identify selectivity patterns

• Perform site-directed mutagenesis of putative recognition motifs in cargo proteins

• Combine with electron microscopy to measure the physical parameters of tethered vesicles:

  • Calculate the distance between vesicles and tethering surfaces

  • Analyze vesicle size distributions

  • Quantify the number of tethered vesicles per unit membrane

These approaches allow researchers to determine both the specificity and mechanism of TBC1D23-mediated cargo selection during vesicle tethering events.